Diamond Biotechnology Salute del bilancio
Salute finanziaria criteri di controllo 4/6
Diamond Biotechnology has a total shareholder equity of NT$612.6M and total debt of NT$301.9M, which brings its debt-to-equity ratio to 49.3%. Its total assets and total liabilities are NT$1.0B and NT$428.9M respectively. Diamond Biotechnology's EBIT is NT$98.7M making its interest coverage ratio 13.6. It has cash and short-term investments of NT$224.1M.
Informazioni chiave
49.3%
Rapporto debito/patrimonio netto
NT$301.86m
Debito
| Indice di copertura degli interessi | 13.6x |
| Contanti | NT$224.14m |
| Patrimonio netto | NT$612.55m |
| Totale passività | NT$428.90m |
| Totale attività | NT$1.04b |
Aggiornamenti recenti sulla salute finanziaria
Nessun aggiornamento
Recent updates
Analisi della posizione finanziaria
Passività a breve termine: 6815's short term assets (NT$673.3M) exceed its short term liabilities (NT$231.8M).
Passività a lungo termine: 6815's short term assets (NT$673.3M) exceed its long term liabilities (NT$197.1M).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: 6815's net debt to equity ratio (12.7%) is considered satisfactory.
Riduzione del debito: 6815's debt to equity ratio has increased from 37.8% to 49.3% over the past 5 years.
Copertura del debito: 6815's operating cash flow is negative, therefore debt is not well covered.
Copertura degli interessi: 6815's interest payments on its debt are well covered by EBIT (13.6x coverage).